The New York Giants could face questions about Cam Skattebo's media appearances following comments he made this week ...

Rhythm Biosciences is entering a new commercial era, with the first sale of its revolutionary Colostat bowel cancer assay ...

Dr. Douglas Lotz steps in as Interim CEO, with a clear focus on patient-first care. Building on a legacy of trusted relationships and life-changing outcomes. At Family Allergy & Asthma, our name ...

Use of single maintenance and reliever therapy (SMART) for moderate-to-severe asthma saved money by improving outcomes, according to a meta-analysis. While SMART is recommended by guidelines, ...

Asthma may not be driven by the molecules scientists have blamed for decades. Researchers have identified “pseudo leukotrienes,” inflammation-triggering compounds formed by uncontrolled free-radical ...

Please provide your email address to receive an email when new articles are posted on . Many parents believe children will outgrow wheeze without seeing a specialist. Many patients also underestimate ...

Researchers from UW-Milwaukee and UW-Madison are studying the link between air pollution and asthma-related school nurse visits at MPS. They'll use satellite data to estimate nitrogen dioxide levels ...

A new option for hard-to-control asthma: The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma. Designed to reduce flare-ups: The injectable ...

What Is Exdensur, and Why Does It Matter? Exdensur (depemokimab) is a new type of ultra long-acting biologic medicine approved by the FDA as an add-on maintenance treatment for severe eosinophilic ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two doses annually. Phase 3 trials demonstrated significant reductions in asthma ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...